In NAFLD patients with hypertension angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been noted as a promising medication, since the renin–angiotensin–aldosterone system is involved in the pathogenesis of both NAFLD and cardiovascular pathologies. This evidence concerns the gene REN and metabolic dysfunction-associated steatotic liver disease.